1
Gary S Gray, Jerry Carson, Kashi Javaherian, Paul D Rennert, Sandra Silver: CTLA4-C&ggr;4 fusion proteins. Repligen Corporation, Amy E Mandragouras Esq, Megan E Williams Esq, Lahive & Cockfiled, September 3, 2002: US06444792 (89 worldwide citation)

CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second pepti ...


2
Clive Wood, Gordon J Freeman: Downmodulating an immune response with multivalent antibodies to PD-1. Genetics Institute, Dana Farber Cancer Institute, Amy E Mandragouras Esq, Megan E Williams Esq, Lahive & Cockfield, October 26, 2004: US06808710 (82 worldwide citation)

The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory ...


3
Beatriz M Carreno, John Leonard: Methods for downmodulating immune cells using an antibody to PD-1. Wyeth, Lahive & Cockfield, Amy E Mandragouras Esq, April 18, 2006: US07029674 (72 worldwide citation)

Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response.


4
Guriq Basi, Jose Saldanha: Humanized antibodies that recognize beta amyloid peptide. Elan Pharma International, Wyeth, Lahive & Cockfield, Amy E Mandragouras Esq, Debra J Milasincic Esq, August 14, 2007: US07256273 (60 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


5
Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M Golden Fleet: Human CTLA-8 and uses of CTLA-8-related proteins. Genetics Institute, Amy E Mandragouras Esq, Peter C Lauro Esq, Lahive & Cockfield, March 28, 2000: US06043344 (50 worldwide citation)

Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.


6
Carl H June: Methods for modulating T cell responses by manipulating intracellular signal transduction. The United States of America represented by the Secretary of the Navy, Amy E Mandragouras Esq, DeAnn F Smith Esq, Lahive & Cockfield, October 14, 2003: US06632789 (50 worldwide citation)

Methods for modulating T cell responses by manipulating intracellular signals associated with T cell costimulation are disclosed. The methods involve inhibiting or stimulating the production of at least one D3-phosphoinositide in a T cell. Production of D3-phosphoinositides can be manipulated by con ...


7
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Wyeth, Neuralab, Lahive & Cockfield, Amy E Mandragouras Esq, Debra J Milasincic Esq, March 13, 2007: US07189819 (48 worldwide citation)

The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


8
John G Gribben, Gordon J Freeman, Lee M Nadler, Paul Rennert, Cindy L Jellis, Edward Greenfield, Gary S Gray: Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies. Repligen Corporation, Dana Farber Cancer Institute, Amy E Mandragouras Esq, DeAnn F Smith Esq, Lahive & Cockfield, April 13, 2004: US06719972 (48 worldwide citation)

Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the ...


9
Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, Nelly Malenkovich: Nucleic acids encoding costimulatory molecule B7-4. Dana Farber Cancer Institute, Lahive & Cockfield, Amy E Mandragouras Esq, Megan E Williams Esq, August 30, 2005: US06936704 (39 worldwide citation)

The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expres ...


10
Tillman U Gerngross: Methods for producing modified glycoproteins. GlycoFi, Lahive & Cockfield, Amy E Mandragouras Esq, Peter W Dini, February 5, 2008: US07326681 (38 worldwide citation)

Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not ...